CD8A and neoplasm: Tumor sections from all treatment groups were (semi)quantitively analyzed for markers of apoptosis (caspase-3), DNA damage (53BP1), cell proliferation (Ki67), CAIX, PD-L1, as well as markers for different immune cell types, including T cells (CD3, CD8, CD4, FOXP3), neutrophils (Ly6G), and macrophages (F4-80) (Figure 6A-B and Figure S7).